Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 5.1% - What's Next?

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) dropped 5.1% during trading on Thursday . The stock traded as low as $126.38 and last traded at $127.98. Approximately 108,859 shares changed hands during trading, a decline of 74% from the average daily volume of 416,135 shares. The stock had previously closed at $134.87.

Analyst Ratings Changes

A number of research analysts recently commented on ASND shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Bank of America boosted their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Oppenheimer cut their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a report on Friday, November 15th. JPMorgan Chase & Co. lowered their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 23rd. Finally, StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $192.07.

Ascendis Pharma A/S Trading Down 2.7 %

The company's fifty day moving average is $133.13 and its 200-day moving average is $133.50. The firm has a market capitalization of $7.78 billion, a P/E ratio of -15.86 and a beta of 0.65.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth approximately $30,000. GAMMA Investing LLC increased its position in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 214 shares during the period. Signaturefd LLC raised its stake in Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 80 shares during the last quarter. Pursue Wealth Partners LLC bought a new stake in Ascendis Pharma A/S in the 3rd quarter valued at $217,000. Finally, Rhumbline Advisers boosted its holdings in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after purchasing an additional 143 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.